Novo Nordisk Restructures Domestic Footprint as Oral Wegovy Pill Outpaces Rival
Novo Nordisk’s oral semaglutide outperforms Eli Lilly’s drug in obesity trial, while the company halts Odense plant construction.…
Novo Nordisk’s Oral Wegovy Smashes Expectations, but Margin Pressure and Rival Threats Cloud the O
Oral Wegovy nearly doubles Q1 sales, Citi boosts long-term forecast to 50B kr, but competition and pricing headwinds…
Novo Nordisk’s Subscription Gamble Meets a Formidable New Rival
Novo Nordisk shares fall 50% from highs as Eli Lilly’s oral GLP-1 pill challenges Wegovy. The firm launches…
Novo Nordisk’s Oral Ambitions Face a Formidable Rival and Fiscal Headwinds
Novo Nordisk touts superior weight loss & tolerability for its oral Wegovy pill vs Lilly’s Foundayo, while launching…
Novo Nordisk Responds to Rival Launch with Clinical Data and Subscription Model
Novo Nordisk releases head-to-head data favoring oral Wegovy over Foundayo and launches a direct-to-consumer subscription plan to retain…
Novo Nordisk Faces Mounting Pressure as Rival Gains Ground
Novo Nordisk faces intense competition from Eli Lilly in the $100B obesity drug market, with clinical data and…
Novo Nordisk Faces Mounting Pressure as Generic Rival Emerges
The Danish pharmaceutical giant’s commanding position in the weight-loss drug market is under significant threat. Novo Nordisk, already…